Abstract Search

ey0019.10-3 | Clinical Trials | ESPEYB19

10.3. Randomized trial of closed-loop control in very young children with type 1 diabetes

J Ware , JM Allen , CK Boughton , ME Wilinska , S Hartnell , A Thankamony , Beaufort C de , U Schierloh , E Frohlich-Reiterer , JK Mader , TM Kapellen , B Rami-Merhar , M Tauschmann , K Nagl , SE Hofer , FM Campbell , J Yong , KK Hood , J Lawton , S Roze , J Sibayan , J Bocchino , C Kollman , R Hovorka , Consortium KidsAP

N Engl J Med. 2022 Jan 20;386(3):209-219. https://pubmed.ncbi.nlm.nih.gov/35045227/Brief Summary: This multicenter, randomized, crossover trial in 74 very young children (age: 1-7 years) with type 1 diabetes (T1D) tested the safety and efficacy of a hybrid closed-loop system for insulin delivery (CamAPS FX) compared with sensor-augmented pump therapy over 16 weeks. The hybrid closed-loop sy...

0 shares

ey0020.8-2 | Clinical Trials – New Treatments | ESPEYB20

8.2. Closed-loop therapy and preservation of C-peptide secretion in type 1 diabetes

CK Boughton , JM Allen , J Ware , ME Wilinska , S Hartnell , A Thankamony , T Randell , A Ghatak , REJ Besser , D Elleri , N Trevelyan , FM Campbell , J Sibayan , P Calhoun , R Bailey , G Dunseath , R Hovorka , CLOuD Consortium

Brief summary: In this multicenter, open-label, parallel-group, randomized trial, 97 adolescents (aged 1016.9 years) were randomized within 21 days after the diagnosis of type 1 diabetes (T1D) to receive either hybrid closed-loop therapy or standard insulin therapy (control) for 24 months. Although closed-loop therapy was associated with better glycemic outcomes, there were no differences in C-peptide between the two groups.The Closed Loop from Ons...

0 shares

ey0016.10-20 | (1) | ESPEYB16

10.20. Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes

G Musolino , K Dovc , CK Boughton , M Tauschmann , JM Allen , Nagl , M Fritsch , J Yong , E Metcalfe , D Schaeffer , M Fichelle , U Schierloh , AG Thiele , D Abt , H Kojzar , JK Mader , S Slegtenhorst , N Ashcroft , ME Wilinska , J Sibayan , N Cohen , C Kollman , SE Hofer , E Frohlich-Reiterer , TM Kapellen , CL Acerini , C de Beaufort , F Campbell , B Rami-Merhar , R Hovorka , Kidsap Consortium

Pediatr Diabetes. 2019 May 29. doi: 10.1111/pedi.12872. [Epub ahead of print]There might be many benefits arising from the artificial pancreas and other new technologies to deliver insulin and measure glucose levels. Whether or not such technological advances will improve the lives of children and families needs to be answered.This study surveyed the experiences of parent...

0 shares

ESPE Yearbook of Paediatric Endocrinology

10.3. Randomized trial of closed-loop control in very young children with type 1 diabetes

8.2. Closed-loop therapy and preservation of C-peptide secretion in type 1 diabetes

10.20. Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day-and-night hybrid closed-loop use in very young children with type 1 diabetes

BiosciAbstracts